```markdown

DISCLAIMER.md


# **DISCLAIMER FOR CVE-2026-0628 RESEARCH AND PROOF-OF-CONCEPT**

**Author:** Sastra Adi Wiguna
**Organization:** Purple Elite Teaming
**Date:** January 29, 2026
**CVE Identifier:** CVE-2026-0628
**Research Title:** Origin CyberAnatomy Spoofing via Malicious WebView: Dissecting CVE-2026-0628 Chromium Extension Privilege Escalation

---

## **1. PURPOSE AND SCOPE**

This research analyzes **CVE-2026-0628**, a high-severity vulnerability in Chromium's WebView policy enforcement mechanism (CVSS v3.1: 8.8). The purpose of this document and accompanying materials is **exclusively for academic, defensive security research, and authorized penetration testing**.

The technical analysis, exploit demonstrations, and proof-of-concept code are provided **solely for the following purposes**:

- **Vulnerability understanding and analysis** for security researchers.
- **Detection engineering** to develop signatures for malicious activity.
- **Mitigation strategy development** for system administrators and browser vendors.
- **Authorized penetration testing and red team assessments** under explicit legal authorization.
- **Responsible disclosure documentation** to assist in patch deployment and security hardening.

---

## **2. RESPONSIBLE USE STATEMENT**

### **2.1 Authorized Use Cases**
Readers and users of this research are **strictly directed** to apply this information **only for defensive purposes**, including but not limited to:

- **Patch deployment verification** for Chrome ≥143.0.7499.192 and Edge ≥143.0.3650.139.
- **Extension blacklisting** via Group Policy Object (GPO) or enterprise management tools.
- **Behavioral detection signature development** (e.g., YARA, Sysmon, Sigma rules).
- **Enterprise browser hardening** through configuration baselines and security policies.
- **Legitimate vulnerability research** conducted in isolated, non-production environments.

### **2.2 Prohibited Use Cases**
The following activities are **explicitly prohibited** and constitute **unauthorized and unethical use** of this research:

- **Offensive use** against any system without explicit, written authorization from the system owner.
- **Weaponization** or integration into exploit kits, malware, or attack frameworks.
- **Distribution to malicious actors** or entities known to engage in cybercrime.
- **Exploitation of production systems**, including but not limited to corporate networks, government systems, or personal devices.
- **Violation of applicable laws**, including computer fraud and abuse statutes, data protection regulations, and intellectual property rights.

---

## **3. LEGAL AND ETHICAL COMPLIANCE**

### **3.1 Compliance with Laws and Regulations**
Users of this research **must comply** with all applicable laws and regulations, including but not limited to:

- **Computer Fraud and Abuse Act (CFAA)** in the United States.
- **General Data Protection Regulation (GDPR)** in the European Union.
- **Local cybersecurity and data protection laws** in the user's jurisdiction.
- **Organizational security policies** governing vulnerability research and penetration testing.

### **3.2 Authorization Requirements**
Any attempt to reproduce or test the vulnerability **must** be conducted under **explicit legal authorization**, including:

- **Written permission** from the owner of the target system.
- **Compliance with organizational policies** for security testing.
- **Adherence to responsible disclosure practices**, including coordination with vendors and affected parties.

Failure to obtain proper authorization **may result in legal consequences**, including civil and criminal liability.

---

## **4. ENVIRONMENTAL RESTRICTIONS**

### **4.1 Isolated Laboratory Requirements**
All technical demonstrations, exploit testing, and vulnerability reproduction **must** be conducted in **isolated laboratory environments** with the following minimum requirements:

- **Virtualized systems** with no network connectivity to production environments or the public internet.
- **Snapshot and rollback capabilities** to ensure containment of any unintended effects.
- **Logging and monitoring** to track all actions and detect anomalies.
- **Restricted access** limited to authorized security personnel.

### **4.2 Prohibited Environments**
Under no circumstances should this research be reproduced or tested in the following environments:

- **Production systems** used for business operations, personal use, or critical infrastructure.
- **Cloud environments** without explicit isolation and authorization.
- **Systems containing sensitive or personal data**, including but not limited to PII, financial records, or intellectual property.
- **Third-party networks or systems** without written consent from the owner.

---

## **5. TECHNICAL AND OPERATIONAL RISKS**

### **5.1 Potential Risks of Reproduction**
Reproducing this vulnerability **carries inherent risks**, including but not limited to:

- **System compromise** due to unintended exploitation or misconfiguration.
- **Data leakage** if testing is conducted in non-isolated environments.
- **Denial-of-service (DoS)** conditions affecting the stability of the test system.
- **Unintended propagation** of malicious code or extensions.

### **5.2 Risk Mitigation Measures**
To mitigate these risks, users **must** implement the following controls:

- **Use non-persistent virtual machines** that can be reverted to a clean state.
- **Disable network connectivity** during testing to prevent accidental exposure.
- **Monitor system logs** for signs of unintended activity.
- **Validate all inputs and outputs** to ensure no malicious payloads are executed outside the test environment.

---

## **6. CITATION AND ATTRIBUTION**

### **6.1 Citation Requirements**
Any reproduction, distribution, or reference to this research **must** include the following:

- **Full preservation of this disclaimer** in all derived works.
- **Proper citation** of the original research, including the author, title, and publication date.
- **Clear attribution** to the corresponding author for any inquiries or clarifications.

### **6.2 Example Citation Format**
```
Sastra Adi Wiguna. (January 2026). *Origin CyberAnatomy Spoofing via Malicious WebView: Dissecting CVE-2026-0628 Chromium Extension Privilege Escalation*. Purple Elite Teaming.
```

---

## **7. PATCH AND MITIGATION RECOMMENDATIONS**

### **7.1 Immediate Actions**
Organizations and individuals **must** take the following steps to mitigate exposure to CVE-2026-0628:

- **Verify patch compliance** for Chrome ≥143.0.7499.192 and Edge ≥143.0.3650.139.
- **Deploy Group Policy Objects (GPO)** to blacklist malicious extensions and restrict WebView usage.
- **Implement behavioral detection rules** (e.g., YARA, Sysmon) to identify exploitation attempts.
- **Conduct security awareness training** to educate users about the risks of installing untrusted extensions.

### **7.2 Long-Term Mitigation Strategies**
- **Enterprise browser hardening** through configuration baselines and security policies.
- **Regular vulnerability assessments** to identify and remediate similar vulnerabilities.
- **Incident response planning** to address potential exploits and breaches.
- **Collaboration with vendors** to report vulnerabilities and validate patches.

---

## **8. CONTACT AND SUPPORT**

### **8.1 Corresponding Author**
For questions regarding defensive security measures, mitigation guidance, or responsible disclosure, contact:

**Name:** Sastra Adi Wiguna
**Organization:** Purple Elite Teaming
**Email:** [REDACTED FOR PUBLIC REPOSITORY]
**GitHub:** [REDACTED FOR PUBLIC REPOSITORY]

### **8.2 Reporting Vulnerabilities**
If you discover additional vulnerabilities or variants of CVE-2026-0628, **please report them responsibly** to the corresponding vendor:

- **Google Chrome Security Team:** [[email protected]](mailto:[email protected])
- **Microsoft Edge Security Team:** [[email protected]](mailto:[email protected])

---

## **9. LIABILITY DISCLAIMER**

### **9.1 No Warranty**
This research is provided **"as is"** without any warranties, express or implied, including but not limited to:

- **Merchantability** or fitness for a particular purpose.
- **Accuracy, completeness, or reliability** of the information.
- **Freedom from errors, omissions, or inaccuracies**.

### **9.2 Limitation of Liability**
The author, contributors, and affiliated organizations **shall not be liable** for any direct, indirect, incidental, special, or consequential damages arising from:

- The use or inability to use this research.
- Unauthorized or improper use of the provided materials.
- Any errors, omissions, or inaccuracies in the documentation.
- Any actions taken based on the information contained herein.

Users assume **full responsibility** for their use of this research and agree to **indemnify and hold harmless** the author and contributors from any claims or liabilities.

---

## **10. FINAL NOTES**

### **10.1 Ethical Research Commitment**
This research adheres to the principles of **responsible disclosure** and **ethical hacking**. The author is committed to **transparency, integrity, and collaboration** with the security community to improve cybersecurity defenses.

### **10.2 Acknowledgment of Risks**
Users acknowledge that reproducing this vulnerability **involves significant risks** and agree to **assume all responsibility** for their actions. The author and contributors **do not endorse or condone** any unauthorized or malicious use of this research.

### **10.3 Encouragement for Responsible Disclosure**
Readers are encouraged to **report vulnerabilities responsibly** and contribute to the **collective effort** of improving cybersecurity. Together, we can create a safer digital environment for all.

---

**© 2026 Sastra Adi Wiguna. All rights reserved.**
This disclaimer is **immutable** and **must** accompany all reproductions or distributions of this research.
```